Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Expands By 4,157.1%

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) was the recipient of a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 178,800 shares, an increase of 4,157.1% from the May 15th total of 4,200 shares. Currently, 1.7% of the shares of the company are sold short. Based on an average trading volume of 239,500 shares, the short-interest ratio is presently 0.7 days.

Analyst Ratings Changes

Separately, HC Wainwright increased their price target on Armata Pharmaceuticals from $7.00 to $9.00 and gave the stock a "buy" rating in a research report on Monday, May 19th.

Armata Pharmaceuticals Trading Down 7.0%

ARMP stock traded down $0.14 during mid-day trading on Friday, reaching $1.87. 17,405 shares of the company's stock were exchanged, compared to its average volume of 69,813. The firm has a market capitalization of $67.66 million, a P/E ratio of -1.14 and a beta of 0.87. The firm has a 50 day moving average of $1.58. Armata Pharmaceuticals has a 12-month low of $0.90 and a 12-month high of $3.42.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.